Application of CHPF gene as gastric cancer treatment target

CN120678930APending Publication Date: 2025-09-23NANJING UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510908973.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-02
Publication Date
2025-09-23

AI Technical Summary

Technical Problem

Existing technologies have limited therapeutic effects in the treatment of locally advanced gastric cancer. How to accurately identify potential beneficiaries and optimize treatment strategies is a key challenge in clinical research, especially the combined application of chemotherapy, immunotherapy and targeted therapy has not been fully explored.

Method used

Using the CHPF gene as a therapeutic target, we develop drugs and reagents targeting CHPF, including siRNA, to inhibit the apoptosis and invasion of gastric cancer cells. By regulating ROS levels and mitochondrial membrane potential, combined therapy with PD-1/PD-L1 inhibitors is performed to establish a precise diagnosis, treatment and prognosis assessment system.

Benefits of technology

It significantly inhibits the invasive ability of gastric cancer cells, increases the pathological complete remission rate, improves patient prognosis, provides new gastric cancer treatment strategies and prognosis evaluation methods, and fills the gap in CHPF research on gastric cancer gene therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120678930A_ABST
    Figure CN120678930A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of gene drugs, and particularly discloses application of a CHPF gene as a gastric cancer treatment target. Researches find that the CHPF gene is highly expressed in gastric cancer tissues and is related to poor prognosis. The invention discloses an application of a CHPF gene nucleic acid molecule or a transcription protein thereof as a therapeutic target in preparation of drugs for inhibiting gastric cancer, and an application of the CHPF gene nucleic acid molecule or the transcription protein thereof as a molecular marker in a gastric cancer prognosis evaluation reagent. Particularly, a reagent (such as siRNA) for silencing the CHPF gene can effectively inhibit the growth of gastric cancer cells, induce apoptosis and reduce the invasion ability of the gastric cancer cells. In addition, the invention further discloses a pharmaceutical composition containing a silent CHPF gene reagent and a PD-1 / PD-L1 inhibitor, and a new strategy and means are provided for diagnosis, prognosis evaluation and treatment of gastric cancer.
Need to check novelty before this filing date? Find Prior Art